Long-term effects of low molecular weight heparin on lipid parameters in hemodialysis patients. 1996

M S Elisaf, and H Bairaktari, and N Germanos, and M Pappas, and E Koulouridis, and N Papagalanis, and K C Siamopoulos
Department of Internal Medicine, Medical School, University of Ioannina, Greece.

OBJECTIVE The long-term effects of the replacement of conventional heparin by low-molecular weight heparin (LMWH) on lipid parameters were examined in a large group of hemodialysis patients. METHODS One-year prospective investigation. METHODS Renal units. METHODS A total of 93 patients aged 12-63 years old receiving hemodialysis for 51 (1-172) months were studied. None of the patients had primary hyperlipidemia, diabetes mellitus, or other secondary causes of dyslipidemia. METHODS In all patients administration of LMWH was introduced in doses 2500-5000 units. METHODS Baseline values of lipoprotein profile prior to the intervention were compared with results obtained after 3, 6 and 12 months of LMWH. RESULTS During of LMWH treatment a small but statistically significant decrease of total and HDL cholesterol (from 200 +/- 45 mg/dl to 185 +/- 42 mg/dl, p < 0.01, and from 45 +/- 11 mg/dl to 42 +/- 10 mg/dl, p < 0.05, respectively), as well as Apo B (from 128 +/- 36 mg/dl to 121 +/- 35 mg/dl, p < 0.001) was noticed. Moreover, triglycerides decreased significantly (from 175 +/- 73 mg/dl to 146 +/- 62 mg/dl, p < 0.001). The beneficial effects of LMWH were more pronounced in patients with dyslipidemia (total cholesterol > 200 mg/dl, or triglycerides > 200 mg/dl) before the replacement of conventional heparin. CONCLUSIONS The long-term use of LMWH instead of conventional heparin for anticoagulation during dialysis has beneficial effects on the lipoprotein profile, especially in patients with dyslipidemia.

UI MeSH Term Description Entries
D008055 Lipids A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) Lipid
D008076 Cholesterol, HDL Cholesterol which is contained in or bound to high-density lipoproteins (HDL), including CHOLESTEROL ESTERS and free cholesterol. High Density Lipoprotein Cholesterol,Cholesterol, HDL2,Cholesterol, HDL3,HDL Cholesterol,HDL(2) Cholesterol,HDL(3) Cholesterol,HDL2 Cholesterol,HDL3 Cholesterol,alpha-Lipoprotein Cholesterol,Cholesterol, alpha-Lipoprotein,alpha Lipoprotein Cholesterol
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M S Elisaf, and H Bairaktari, and N Germanos, and M Pappas, and E Koulouridis, and N Papagalanis, and K C Siamopoulos
January 1992, ASAIO journal (American Society for Artificial Internal Organs : 1992),
M S Elisaf, and H Bairaktari, and N Germanos, and M Pappas, and E Koulouridis, and N Papagalanis, and K C Siamopoulos
January 1990, ASAIO transactions,
M S Elisaf, and H Bairaktari, and N Germanos, and M Pappas, and E Koulouridis, and N Papagalanis, and K C Siamopoulos
January 1997, Journal of nephrology,
M S Elisaf, and H Bairaktari, and N Germanos, and M Pappas, and E Koulouridis, and N Papagalanis, and K C Siamopoulos
January 1998, Journal of the Formosan Medical Association = Taiwan yi zhi,
M S Elisaf, and H Bairaktari, and N Germanos, and M Pappas, and E Koulouridis, and N Papagalanis, and K C Siamopoulos
January 2009, Blood purification,
M S Elisaf, and H Bairaktari, and N Germanos, and M Pappas, and E Koulouridis, and N Papagalanis, and K C Siamopoulos
January 1995, Haemostasis,
M S Elisaf, and H Bairaktari, and N Germanos, and M Pappas, and E Koulouridis, and N Papagalanis, and K C Siamopoulos
January 1985, Klinische Wochenschrift,
M S Elisaf, and H Bairaktari, and N Germanos, and M Pappas, and E Koulouridis, and N Papagalanis, and K C Siamopoulos
January 1999, Nephron,
M S Elisaf, and H Bairaktari, and N Germanos, and M Pappas, and E Koulouridis, and N Papagalanis, and K C Siamopoulos
January 1991, ASAIO transactions,
M S Elisaf, and H Bairaktari, and N Germanos, and M Pappas, and E Koulouridis, and N Papagalanis, and K C Siamopoulos
November 1985, Kidney international,
Copied contents to your clipboard!